INTELLIA THERAPEUTICS, INC. Revenue
INTELLIA THERAPEUTICS, INC. (NTLA) reported Revenue of $7.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $7.66M, a 46.23% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $15.05M, a 9.50% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $23.02M, a 78.79% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $13.78M, a 51.27% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $67.67M, a 16.92% increase from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $57.88M, a 59.55% increase from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $36.27M, a 30.40% decline from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $52.12M, a 57.69% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.66M 10-Q · filed 2026-08-06 | $22.71M 10-Q · filed 2026-08-06 | $45.72M derived: sum of 3 quarters · filed 2026-08-06 | $59.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.05M 10-Q · filed 2026-05-11 | $38.06M derived: sum of 2 quarters · filed 2026-05-11 | $51.85M derived: sum of 3 quarters · filed 2026-05-11 | $66.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.80M derived: sum of 2 quarters · filed 2026-02-26 | $51.04M derived: sum of 3 quarters · filed 2026-08-06 | $67.67M 10-K · filed 2026-02-26 |
| 2025-09-30 | $13.78M 10-Q · filed 2025-11-06 | $28.03M derived: sum of 2 quarters · filed 2026-08-06 | $44.65M 10-Q · filed 2025-11-06 | $57.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.24M 10-Q · filed 2026-08-06 | $30.87M 10-Q · filed 2026-08-06 | $43.75M derived: sum of 3 quarters · filed 2026-08-06 | $52.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $16.63M 10-Q · filed 2026-05-11 | $29.50M derived: sum of 2 quarters · filed 2026-05-11 | $38.61M derived: sum of 3 quarters · filed 2026-05-11 | $45.57M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $12.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.98M derived: sum of 2 quarters · filed 2026-02-26 | $28.94M derived: sum of 3 quarters · filed 2026-02-26 | $57.88M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.11M 10-Q · filed 2025-11-06 | $16.07M derived: sum of 2 quarters · filed 2025-11-06 | $45.00M 10-Q · filed 2025-11-06 | $43.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $6.96M 10-Q · filed 2025-08-07 | $35.89M 10-Q · filed 2025-08-07 | $33.98M derived: sum of 3 quarters · filed 2026-02-26 | $45.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $28.93M 10-Q · filed 2025-05-08 | $27.02M derived: sum of 2 quarters · filed 2026-02-26 | $39.01M derived: sum of 3 quarters · filed 2026-02-26 | $52.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.07M derived: sum of 2 quarters · filed 2026-02-26 | $23.67M derived: sum of 3 quarters · filed 2026-02-26 | $36.27M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.99M 10-Q · filed 2024-11-07 | $25.59M derived: sum of 2 quarters · filed 2024-11-07 | $38.19M 10-Q · filed 2024-11-07 | $51.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $13.59M 10-Q · filed 2024-08-08 | $26.20M 10-Q · filed 2024-08-08 | $39.77M derived: sum of 3 quarters · filed 2025-02-27 | $53.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $12.61M 10-Q · filed 2024-05-09 | $26.18M derived: sum of 2 quarters · filed 2025-02-27 | $39.45M derived: sum of 3 quarters · filed 2025-02-27 | $53.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $26.84M derived: sum of 2 quarters · filed 2025-02-27 | $40.87M derived: sum of 3 quarters · filed 2025-02-27 | $52.12M 10-K · filed 2025-02-27 |
| 2022-09-30 | $13.27M 10-Q · filed 2023-11-09 | $27.30M derived: sum of 2 quarters · filed 2023-11-09 | $38.55M 10-Q · filed 2023-11-09 | $51.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $14.03M 10-Q · filed 2023-08-03 | $25.28M 10-Q · filed 2023-08-03 | $38.14M derived: sum of 3 quarters · filed 2024-02-22 | $45.34M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $11.25M 10-Q · filed 2023-05-04 | $24.11M derived: sum of 2 quarters · filed 2024-02-22 | $31.31M derived: sum of 3 quarters · filed 2024-02-22 | $37.86M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $12.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $20.06M derived: sum of 2 quarters · filed 2024-02-22 | $26.61M derived: sum of 3 quarters · filed 2024-02-22 | $33.05M 10-K · filed 2024-02-22 |
| 2021-09-30 | $7.20M 10-Q · filed 2022-11-03 | $13.75M derived: sum of 2 quarters · filed 2022-11-03 | $20.20M 10-Q · filed 2022-11-03 | $26.79M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $6.55M 10-Q · filed 2022-08-04 | $12.99M 10-Q · filed 2022-08-04 | $19.59M derived: sum of 3 quarters · filed 2022-08-04 | $41.81M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $6.45M 10-Q · filed 2022-05-05 | $13.04M derived: sum of 2 quarters · filed 2022-05-05 | $35.26M derived: sum of 3 quarters · filed 2022-05-05 | $51.52M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $6.59M 10-K · filed 2021-02-26 | $28.82M derived: sum of 2 quarters · filed 2021-11-04 | $45.08M derived: sum of 3 quarters · filed 2021-11-04 | $57.99M 10-K · filed 2023-02-23 |
| 2020-09-30 | $22.22M 10-Q · filed 2021-11-04 | $38.48M derived: sum of 2 quarters · filed 2021-11-04 | $51.40M 10-Q · filed 2021-11-04 | $62.34M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $16.26M 10-Q · filed 2021-08-05 | $29.18M 10-Q · filed 2021-08-05 | $40.12M derived: sum of 3 quarters · filed 2021-08-05 | $50.73M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $12.92M 10-Q · filed 2021-05-06 | $23.85M derived: sum of 2 quarters · filed 2021-05-06 | $34.47M derived: sum of 3 quarters · filed 2021-05-06 | $45.59M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $10.94M 10-K · filed 2021-02-26 | $21.55M derived: sum of 2 quarters · filed 2021-02-26 | $32.67M derived: sum of 3 quarters · filed 2021-02-26 | $43.10M 10-K · filed 2022-02-24 |
| 2019-09-30 | $10.62M 10-K · filed 2021-02-26 | $21.73M derived: sum of 2 quarters · filed 2021-02-26 | $32.17M 10-Q · filed 2020-11-05 | $40.05M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $11.12M 10-K · filed 2021-02-26 | $21.55M 10-Q · filed 2020-08-06 | $29.43M derived: sum of 3 quarters · filed 2021-02-26 | $36.84M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $10.43M 10-K · filed 2021-02-26 | $18.31M derived: sum of 2 quarters · filed 2021-02-26 | $25.72M derived: sum of 3 quarters · filed 2021-02-26 | $33.40M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $7.88M 10-K · filed 2020-02-27 | $15.29M derived: sum of 2 quarters · filed 2020-02-27 | $22.96M derived: sum of 3 quarters · filed 2020-02-27 | $30.43M 10-K · filed 2021-02-26 |
| 2018-09-30 | $7.41M 10-K · filed 2020-02-27 | $15.09M derived: sum of 2 quarters · filed 2020-02-27 | $22.55M 10-Q · filed 2019-10-31 | $29.22M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $7.68M 10-K · filed 2020-02-27 | $15.15M 10-Q · filed 2019-08-01 | $21.81M derived: sum of 3 quarters · filed 2020-02-27 | $29.13M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $7.47M 10-K · filed 2020-02-27 | $14.14M derived: sum of 2 quarters · filed 2020-02-27 | $21.45M derived: sum of 3 quarters · filed 2020-02-27 | $27.37M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $6.67M 10-K · filed 2019-02-27 | $13.98M derived: sum of 2 quarters · filed 2019-02-27 | $19.90M derived: sum of 3 quarters · filed 2019-02-27 | $26.12M 10-K · filed 2020-02-27 |
| 2017-09-30 | $7.32M 10-K · filed 2019-02-27 | $13.23M derived: sum of 2 quarters · filed 2019-02-27 | $19.45M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $5.92M 10-K · filed 2019-02-27 | $12.13M 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $6.21M 10-K · filed 2019-02-27 | |||
| 2016-12-31 | $16.48M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |